Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
Holding MBRX?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$1.26Last Year’s EPS
-$5.02Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 11, 2024
|% Change Since: -34.51%
|Next Earnings Date:Mar 20, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress and potential in the Phase III MIRACLE trial, strong efficacy in Phase II data, and the extended patent life of annamycin. However, challenges remain in recruitment, financial constraints, and the inherent risks of biotech trials.Company Guidance
During the Q3 2024 earnings call, Moleculin Biotech's executives, Walter Klemp and John Waymack, provided detailed guidance on the company's progress and future plans. They highlighted the significant potential of annamycin, a Phase III cancer drug, which is designed to be 100% non-cardiotoxic and avoids cross-resistance with existing AML therapies. The company reported a 50% complete remission rate in second-line AML patients during Phase II trials, significantly outperforming the standard of care. The upcoming Phase III MIRACLE trial will employ an adaptive trial design to optimize dosing, with the potential to dramatically reduce approval risk. The trial is expected to enroll 330 patients, with interim data from 75 to 90 patients anticipated by mid-2026. Moleculin's financial position includes $9.4 million in cash, expected to support operations into Q1 2025. The company is focused on accelerating patient recruitment across 60 sites globally and remains optimistic about the drug's market potential given its expected efficacy and unmet need in AML treatment.Strong Efficacy in Phase II Data
Reported a 50% complete remission rate in second-line AML patients, more than double the expected performance from existing therapies. Additionally, bone marrow transplants in subjects with response have increased to 4 of the 9 patients.
Potential for Accelerated Approval
The MIRACLE trial design and its adaptive nature allow for early unblinding, potentially shortening the approval timeline and reducing risk for investors.
Extended Patent Life
Annamycin is patent protected through 2040, offering a long remaining patent life for a Phase III cancer drug.
Financial Position and Milestones
Ended the quarter with $9.4 million in cash, enough to reach into Q1 of 2025, with key data readouts expected in 2025 and 2026.
---
MBRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MBRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 11, 2024 | $2.55 | $2.51 | -1.57% |
| Aug 14, 2024 | $2.35 | $2.50 | +6.38% |
| May 13, 2024 | $4.76 | $4.67 | -1.89% |
| Mar 22, 2024 | $5.70 | $5.25 | -7.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Moleculin Biotech (MBRX) report earnings?
Moleculin Biotech (MBRX) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is Moleculin Biotech (MBRX) earnings time?
Moleculin Biotech (MBRX) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MBRX EPS forecast?
MBRX EPS forecast for the fiscal quarter 2024 (Q4) is -$1.26.
---